Long‐term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. Issue 2 (2nd December 2016)

• Record Type: Journal Article
• Authors: KINJO, Manami; SEKIGUCHI, Yuki; YOSHIMURA, Yasukuni; NUTAHARA, Kikuo
• Is Part Of: LUTS. Volume 10:Issue 2(2018)
• Page Start: 148
• Page End: 152
• Publication Date: 2016-12-02
• Subjects: β3‐adrenoreceptor agonist -- antimuscarinic agent -- female -- overactive bladder -- persistence; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12151
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract : Objectives: To compare persistence with medication and the reasons for discontinuation of mirabegron or solifenacin therapy up to12 months in women with overactive bladder (OAB). Methods: Female OAB patients who presented to women's urology clinics were enrolled in a prospective, randomized, two‐arm study. Patients were randomized to receive mirabegron at 25–50 mg ( n = 76) or solifenacin at 2.5–5 mg ( n = 72). The persistence rate and the reasons for discontinuation were investigated up to 12 months. Results: The 12‐month persistence rate was 12.2% in the mirabegron group versus 20.1% in the solifenacin group and there were no significant differences of the persistence rates during the study (n.s). Patients discontinued treatment because of lack of efficacy (21.6%), spontaneous improvement (18.2%), and side‐effects (17.6%), while 19.6% were lost to follow up. Discontinuation due to side‐effects was significantly more frequent in the solifenacin group than the mirabegron group (27.3 vs. 7.9%, P < 0.05). In contrast, discontinuation due to lack of efficacy was significantly more frequent in the mirabegron group than the solifenacin group (36.8 vs. 5.6%, P < 0.05). Conclusions: This study demonstrated low persistence rates over 12 months for both mirabegron and solifenacin, although the reasons for discontinuation were somewhat different.